Last reviewed · How we verify
MSCs Transplantation
At a glance
| Generic name | MSCs Transplantation |
|---|---|
| Sponsor | Chinese Academy of Sciences |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- fever
- headache
- dizziness
- transient increase of muscle tension
Key clinical trials
- Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Acute Stroke Infarct (PHASE1, PHASE2)
- Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease (PHASE1)
- Tolerance by Engaging Antigen During Cellular Homeostasis (PHASE1)
- PT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver Failure (EARLY_PHASE1)
- Phase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA (PHASE1, PHASE2)
- Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy (PHASE1)
- Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT (PHASE1)
- Umbilical Cord-derived Mesenchymal Stem Cell Infusion in the Management of Adult Liver Cirrhosis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSCs Transplantation CI brief — competitive landscape report
- MSCs Transplantation updates RSS · CI watch RSS
- Chinese Academy of Sciences portfolio CI